The following is a summary of the Bioventus Inc. (BVS) Q3 2024 Earnings Call Transcript:

Financial Performance:

• Bioventus reported a Q3 revenue of $139 million, a 15% growth from the previous year, driven by strong performance across all three business segments.

• Adjusted EBITDA for the quarter increased by $2 million, reaching over $24 million, an 8% increase over the prior year.

• Adjusted net income was $5 million, up 10% compared to the prior year, with adjusted earnings per share at $0.06 for the quarter.

Business Progress:

• The company continues to experience robust double-digit organic revenue growth due to effective execution across all businesses, particularly in surgical solutions and pain treatments.

• Bioventus is making strategic investments in medical education and commercial effectiveness to expand its market share, particularly in surgical solutions and pain treatments.

• The company is progressing with the divestiture of its advanced rehabilitation business, expecting to close the transaction by early next year.

Opportunities:

• Bioventus is positioned to drive sustained double-digit revenue growth via line extensions and penetrating additional surgical markets including neurosurgery and general surgery internationally.

• There are opportunities for geographic expansion in pain treatments, leveraging clinical differentiation and robust private payer coverage.

Risks:

• The company faces a short-term slowdown in the growth of its bone graft substitutes (BGS) due to supply chain management issues requiring adjustments in distributor relationships.

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.